Jump to content

User:MomentousOccassion/sandbox

From Wikipedia, the free encyclopedia
< User:MomentousOccassion

This is an old revision of this page, as edited by MomentousOccassion (talk | contribs) at 19:43, 27 November 2023 (→Programs). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Women's Alzheimer's Movement

Maria Shriver

Brooke Eby

Bryan Randall

https://brevardalz.org/alzheimers-info/famous-people-with-dementia/

Banner Alzheimer's Institute

Dr E. Reiman and Dr P Tariot

https://www.nia.nih.gov/health/alzheimers-disease-research-centers

https://clinicaltrials.gov/study/NCT01998841

Crenezumab


Banner Alzheimer’s Institute is a research and care center for Alzheimer’s disease and related dementias that also offers support services for families of individuals with these conditions.[1][2] Its mission is to end Alzheimer’s disease without losing a generation, set a new standard of care for patients and families, and forge a model of collaboration in biomedical research.[2][1]

The Institute was founded in 2006 in Phoenix, Arizona as part of Banner Health.[3][2] It now has facilities in Phoenix and Tucson, as well as a sister organization in Sun City, Arizona – Banner Sun Health Research Institute. Its co-founders are Dr. Eric Reiman, who is currently the Institute’s executive director, and Dr. Pierre N. Tariot.[2][4]

The Institute collaborates with a wide range of international, national and local scientific, medical, academic and community partners, including the Arizona Alzheimer’s Consortium, the AD Genetics Consortium, ASU-Banner Neurodegenerative Research Collaborative, Dementia ECHO, and the Brain and Body Donation Program.[5][6][7][8]

Research and Scientific Contributions

Banner Alzheimer’s Institute receives millions of dollars in funding to research ways to fight Alzheimer’s and related dementias and increase understanding of these conditions. Studies include prevention trials that work with cognitively normal individuals that may be at an increased risk of developing Alzheimer’s related symptoms as well as studies for individuals with memory loss including Alzheimer’s disease (AD) and mild cognitive impairment (MCI). Funding comes from agencies such as the National Institutes of Health (NIH) – particularly the National Institute on Aging - as well as other organizations, including the Banner Alzheimer’s Foundation.[9][10][11]

Prevention Research

In May of 2012, Banner Alzheimer’s Institute announced the Alzheimer’s Prevention Initiative (API), a large partnership between researchers, academics, and other stakeholders, to find and support approval for an effective Alzheimer’s prevention therapy by 2025.[12][13] Its work includes conducting clinical trials in adults at high risk for developing symptoms of Alzheimer’s, operating large-scale participant recruitment registries, developing data and biological sharing programs, and developing and using new research methods and strategies to evaluate prevention treatments.  Its most significant research projects have been the Autosomal Dominant Alzheimer’s Disease (ADAD) Colombia Trial and the Generation Program[14].[13]

API ADAD Colombia Trial

The API ADAD Colombia Trial was the Institute’s first prevention trial. In 2012 along with the NIH, the University of Antioquia in Colombia, and Genentech (a member of the Roche Group), announced the $100 million, multi-year trial.[15] (rare genetic mutation). The API ADAD trial investigated whether (crenezumab) could stave off the disease in members of a large extended family in Colombia who share a rare genetic mutation that typically triggers Alzheimer’s symptoms around age 45.Can the drug could reduce their chances of developing symptoms, preserve their memory and thinking abilities and slow the progression of Alzheimer’s biomarkers. In June 2022, final results

API Generation Program

Alzheimer’s Prevention Registry

Other Areas of Research

BAI's study portfolio also includes trials with investigational therapeutic interventions, several non-interventional longitudinal studies, and brain imaging-only trials that are aimed at advancing knowledge of Alzheimer’s disease and other dementias. These studies include: Medicines that may help memory and thinking, Drugs that hope to stop or slow signs of the disease, Immunotherapies such as vaccines aimed at helping your body fight off the disease, Studying people with very early signs of memory loss, New techniques for taking pictures of the brain, New ways to spot the disease early on and Studies to understand the disease in minority populations such as Hispanic, Native American or African American.

Programs

Patient and Family Care, Support and Education

Dementia Care Partners Program

Dementia Untangled

First Responder Training

Facilities

Phoenix, Tucson

Sun City

Memory Care Centers

Key Staff

  • Dr. Eric Reiman: Co-founder and executive director of Banner Alzheimer’s Institute
  • Dr. Pierre Tariot: Co-founder of Banner Alzheimer’s Institute

Sourcing

https://www.nytimes.com/2012/05/16/health/research/prevention-is-goal-of-alzheimers-drug-trial.html

https://www.usatoday.com/story/news/health/2022/06/16/closely-watched-alzheimers-study-fails-prevent-advance-disease/7639930001/

https://www.usatoday.com/story/news/health/2022/06/16/closely-watched-alzheimers-study-fails-prevent-advance-disease/7639930001/

https://www.usatoday.com/story/news/health/2022/08/19/aerobic-exercise-and-simple-stretching-may-both-lower-alzheimers-risk/10328732002/

https://www.nytimes.com/2022/06/16/health/alzheimers-drug-crenezumab.html#:~:text=The%20drug%2C%20crenezumab%2C%20failed%20to,effective%20therapies%20for%20the%20disease

https://www.guidestar.org/profile/20-4862361

https://hbr.org/sponsored/2019/09/arizona-the-new-frontier-in-technology-and-health-care

  1. ^ a b Adams, Claire; Hendrie, Kyle; James, Michelle; Tsai, Po-Heng (2023-10-10). "It May Not Be So Typical: Distinguishing Frontotemporal Dementia From Behavioral Variant Alzheimer's Disease". The Primary Care Companion for CNS Disorders. 25 (5): 49348. doi:10.4088/PCC.22alz03400. ISSN 2155-7780.
  2. ^ a b c d "Healthcare Hero Awards". www.bizjournals.com. Retrieved 2023-11-22.
  3. ^ "Banner Alzheimers Foundation - GuideStar Profile". www.guidestar.org. Retrieved 2023-11-22.
  4. ^ "Mutation Protected Man From Alzheimer's Disease, Hinting at Treatment". New York Times.
  5. ^ "ASU, Banner Health launch Alzheimer's, Parkinson's research center". www.bizjournals.com. Retrieved 2023-11-22.
  6. ^ "Alzheimer's Disease Genetics Consortium (ADGC)". Nature Index. 2023-10-31. Retrieved 2023-11-22.
  7. ^ "Banner Alzheimer's Institute expands training, mentoring in dementia care". AZ Big Media. 2022-11-08. Retrieved 2023-11-22.
  8. ^ "Arizona: The New Frontier in Technology and Health Care - SPONSOR CONTENT FROM ARIZONA COMMERCE AUTHORITY". Harvard Business Review. 2019-09-18. ISSN 0017-8012. Retrieved 2023-11-22.
  9. ^ "Diagnosing CTE During Life | The Brink". Boston University. Retrieved 2023-11-22.
  10. ^ McVeigh, Jim (2014-08-06). "NIH Renews Funding of Longitudinal Study of Earliest Alzheimer's Disease Changes". Mayo Clinic News Network. Retrieved 2023-11-22.
  11. ^ "Alzheimer's Disease Research Centers". National Institute on Aging. Retrieved 2023-11-22.
  12. ^ "Alzheimer's Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic Treatments". National Library of Medicine.
  13. ^ a b "The Alzheimer's Prevention Initiative | (API)". alzheimerspreventioninitiative.com. Retrieved 2023-11-27.
  14. ^ "Alzheimer's Prevention Initiative: a proposal to evaluate presymptomatic treatments as quickly as possible". National Library of Medicine.
  15. ^ "Hoping to Crack Alzheimer's, Together as a Family". New York Times.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=User:MomentousOccassion/sandbox&oldid=1187148405"